iSpecimen approves Foldlab AI deal with reverse split vote for iSpecimen stock

Published on 10/14/2026 at 02:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

iSpecimen won 791,600 votes for its AI deal on October 9, 2026. iSpecimen stock faces a 1-for-10 to 1-for-100 vote October 30, 2026.

Foldlab AI deal and shareholder vote

Stockholders approved the Foldlab AI asset acquisition on October 9, 2026, with 791,600 votes in favor.
The proposed reverse split ranges from 1-for-10 to 1-for-100, with the vote scheduled for October 30, 2026.
iSpecimen had 2,518,590 shares outstanding and entitled to vote as of August 12, 2026.

ISPC, US45032V3069, Illustration mit AI erstellt.

iSpecimen Inc. (ISIN US45032V3069) secured 791,600 votes for its Foldlab AI asset acquisition at the October 9, 2026 special meeting, while the proposed reverse split moved to a later vote. The result leaves iSpecimen stock tied to a corporate action that could materially change its share count and trading price.

Three votes shaped the timeline

On October 9, 2026, stockholders approved the Foldlab AI asset acquisition by 791,600 votes to 21,269, with 88 abstentions and 474,590 broker non-votes, according to StockTitan. The same filing says Proposals 1, 3 and 5 also passed, including authorization for future financing transactions.

The record date was August 12, 2026, when 2,518,590 common shares were issued, outstanding and entitled to vote. On September 29, 2026, iSpecimen also announced a hospital validation project involving more than 1,700 human specimens, according to StockTitan.

What happens on October 30?

Proposal 2 was adjourned to October 30, 2026, at 10:00 a.m. Eastern Time. The reverse split authorization covers a ratio from 1-for-10 to 1-for-100, with the exact ratio left to the board, and approval requires votes cast for the measure to exceed votes cast against it, according to StockTitan.

Online and phone voting closes at 11:59 p.m. Eastern Time on October 29, 2026. The filing also states that brokers may vote uninstructed shares held in street name because the reverse split proposal is treated as a routine matter under broker-voting rules.

Market value remains compressed

iSpecimen's market capitalization was USD 2.7 million as of October 13, 2026, while its 52-week range was USD 1.02 to USD 36.32. The gap between that market value and the broad proposed split ratio makes the October 30 vote the next concrete corporate milestone for the Nasdaq-listed company.

Dates investors can track

The October 29 voting deadline comes one day before the adjourned meeting. The October 9 approvals already authorized financing flexibility that may exceed 19.99 percent of the shares outstanding and future securities priced at a discount of up to 80 percent from the applicable lowest volume weighted average price.

Market context: Market report Nasdaq Composite.